Compare HAS & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAS | HALO |
|---|---|---|
| Founded | 1923 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 12.0B |
| IPO Year | 1994 | 2001 |
| Metric | HAS | HALO |
|---|---|---|
| Price | $90.22 | $107.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $109.50 | $99.56 |
| AVG Volume (30 Days) | 1.3M | ★ 2.0M |
| Earning Date | 10-20-2026 | 11-02-2026 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.51 | ★ 3.11 |
| Revenue | ★ $5,365,900,000.00 | $151,862,000.00 |
| Revenue This Year | $7.54 | $32.72 |
| Revenue Next Year | $6.79 | $10.61 |
| P/E Ratio | ★ $35.09 | $36.16 |
| Revenue Growth | ★ 13.06 | N/A |
| 52 Week Low | $69.50 | $61.23 |
| 52 Week High | $106.98 | $116.85 |
| Indicator | HAS | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 54.81 |
| Support Level | $84.12 | $104.49 |
| Resistance Level | $89.20 | $111.15 |
| Average True Range (ATR) | 2.02 | 3.04 |
| MACD | -0.04 | -0.71 |
| Stochastic Oscillator | 33.89 | 42.53 |
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Peppa Pig, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and has since divested noncore lines from the tie-up. Furthermore, the addition of Dungeons & Dragons Beyond in 2022 offers the firm access to around 20 million digital tabletop players.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.